Objective: To measure plasma N-terminal fragments of pro-B-type natriuretic peptides (NTproBNP) and cardiac troponin T (cTnT) concentration in hospitalized dogs and relate these markers to underlying conditions and evaluate their potential as prognostic markers in dogs with systemic inflammatory response syndrome (SIRS).
INTRODUCTION
The systemic inflammatory response syndrome (SIRS) characterizes the systemic repercussions of inflammation. The list of underlying TA B L E 1 Clinical criteria for the diagnosis of SIRS (modified from Hauptman et al, 2 with alterations in white blood cell count to adhere with the reference ranges of the clinical laboratory and temperature ranges as applied in clinics)
Parameter

Limit Unit
Heart frequency >120 bpm
Respiratory rate <20 rpm Temperature <38 or >39
• C Leukocytosis/leukopenia >16,000 or <5,000 / L Left shift on blood smear >3 % of a left shift) variables (Table 1) . 2 The diagnosis of SIRS recognizes the presence of clinical signs compatible with systemic inflammation, but the criteria are overly sensitive and poorly specific. 2 Cardiac dysfunction secondary to systemic inflammation has been reported in human medicine, and is also known as myocardial hibernation. 3, 4 Myocardial hibernation has been reported in critically ill human patients and studied in dogs with experimentally induced sepsis. [4] [5] [6] [7] It is characterized by increased end-diastolic and end-systolic ventricular volumes, 8 and systolic 3 and diastolic 7 ventricular dysfunction. 5 Whether myocardial hibernation serves as a protective mechanism of the body during systemic inflammation, or whether it has a negative impact on survival is unknown. 5, 9 Myocardial hibernation has been associated with increased blood concentrations of cardiac troponins (cTn) 10, 11 and natriuretic peptides [12] [13] [14] in people with SIRS, and some studies have found concentrations of cTn and the N-terminal portion of pro-brain natriuretic peptide (NT-proBNP) to be correlated with the degree of cardiac dysfunction and with plasma concentrations of inflammatory cytokines. 9, 15 Very little is known about myocardial hibernation in dogs with naturally occurring disease, although it is likely to occur. 16, 17 Recent data suggest that plasma concentrations of cardiac biomarkers are increased in dogs with SIRS. [18] [19] [20] As these cardiac biomarkers may help in the diagnosis of cardiac dysfunction and the evaluation of prognosis in people with SIRS, 9,21,22 they may also be useful to evaluate dogs with SIRS.
Cardiac troponins T and I (cTnT and cTnI, respectively) are sensitive and specific for the detection of myocardial ischemic necrosis or reversible myocardial injury, and increased plasma cTnT and cTnI concentrations are associated with a poorer prognosis in critically ill people. 23, 24 Cardiac troponins have been studied in veterinary patients with cardiac disease, 25 and are also increased and associated with poor prognosis in other syndromes such as gastric dilation and volvulus (GDV), 25, 26 trauma, 25, 27 infections, [28] [29] [30] [31] [32] and SIRS. 19, 20, 33 Brain natriuretic peptide (BNP) and NT-proBNP are quantitative markers of ventricular wall stress with high sensitivity and specificity for cardiac insult. 12 Several studies have associated increases in plasma BNP and NT-proBNP in people with sepsis and SIRS with myocardial hibernation and poor prognosis. 9, 12, 13, 15 In veterinary medicine, increased plasma NT-proBNP concentrations have been demonstrated in dogs with babesiosis and in dogs with traumatic, neurological, and gastrointestinal diseases. 32, 34 We hypothesized that plasma cTnT and NT-proBNP would increase during hospitalization, vary in magnitude according to the underlying etiology, and serve as a prognostic marker in canine patients with SIRS.
MATERIALS AND METHODS
All dogs that were examined in the emergency service of the University of Liège between January and August 2010 were considered for inclusion. Dogs were enrolled if SIRS was diagnosed based on the suspicion of an underlying disease process known to trigger the systemic inflammatory response and the finding of 2 or more abnormalities of the following clinical (temperature, heart rate, and respiratory rate) and basic laboratory parameters (leukocyte counts). 2 The cutoff values for white blood cell counts were modified from the original paper to adhere with the reference ranges of our own clinical laboratory ( Baseline plasma concentrations of cTnT and NT-proBNP were assessed on blood sampled prior to starting any treatment (T0), and on samples obtained after 6 (T6), 12 (T12), 24 hours (T24), and every other day thereafter (T72, T120, etc.) until hospital discharge or death. Short-term survival was defined as patient discharge from the hospital, while long-term survival was defined as the patient being alive 1 month after discharge from the hospital. All long-term survivors were invited to a recheck "control" examination occurring between 1 month and 1 year after hospital discharge, where blood was again collected for analysis. All blood samples were divided into EDTA (4 mL) and serum (2 mL) tubes that were centrifuged and separated within 15 minutes, with the serum or plasma stored at -80 • C until analysis.
A commercial electrochemiluminescence kit, * with a lower limit of detection of 0.010 ng/mL, a limit of linearity of 25.00 ng/mL, and a coefficient of variation less than 5% for values above 0.06 ng/mL, was used to measure serum cTnT. 47 The kit detected 2 epitopes of the central part of human cTnT (125-131 and 135-147), which are highly conserved in canine cTnT (one substitution in the first epitope and 100% homology in the second), and has previously been used in veterinary research. 47, 48 Reported values in healthy dogs are less than 0.010 ng/mL. 27, 49 A commercially available sandwich enzyme immune assay † with an upper limit of detection of 3,000 pmol/L was used to measure NTproBNP. Patient plasma and an immunoaffinity purified sheep detection antibody conjugated to horseradish peroxidase were incubated for 5 hours at 20 • C in microtiter plates with capture antibody (anti-NT-proBNP) bound to the wells. The wells were then washed and tetramethylbenzidine was added and incubated for 40 minutes, after which a stop solution was added and bound NT-proBNP was quantified by an ELISA plate reader. All plates were run with calibration and control solutions, yet for financial reasons only the first plate was run in duplicate.
Statistical methods
Statistical analysis was performed using a commercially available Only dogs that survived, died of natural causes, or were euthanized for prognostic reasons were included in the assessment of prognostic value of the evaluated parameters. Statistical significance was set at a P-value < 0.05.
RESULTS
Fifty-eight purebred and 11 mixed-breed dogs were included in the study. The most commonly represented breeds were Bernese Mountain Dog (n = 8), German Shepherd Dog (n = 6), Great Dane (n = 4), Jack Russell Terrier (n = 4), and Belgian Shepherd Dog (n = 3). There 
Biomarker analysis
Plasma concentrations of cTnT and NT-proBNP both changed significantly over time (P < 0.0001). Concentrations of cTnT and NT-proBNP at each timepoint are displayed in Figures 2 and 3 , respectively.
Twenty-eight of 69 dogs had at least 1 time point during hospitalization at which cTnT was detectable, while none of the dogs had measurable cTnT concentrations at the control visit. Plasma cTnT concentration was significantly higher at T12, T24, and T72 compared to concentrations at presentation and at the control visit (Table 2) .
Plasma NT-proBNP concentrations were measurable in all dogs at all timepoints. Plasma NT-proBNP concentrations were significantly higher at T24, T72, and T120 compared to T0, T6, T12, and T1m.
Median concentrations did not differ significantly between T24 
Correlation of biomarkers with underlying disease, prognosis, and each other
Statistical analysis did not identify any influence of the underlying disease category on cTnT and NT-proBNP concentrations (P = 0.1618 and 0.084, respectively). Regardless of the specific timepoint, detectable 
DISCUSSION
This study demonstrated changes in cardiac biomarkers during hospitalization in a population of canine patients with SIRS. Troponin T0  T6  T12  T24  T72  T120  T1m   T0  1 Significant differences are indicated in bold with an asterisk (*). cTnT concentrations appear to agree with the rapid rise and sustained increase described in other reports. In contrast, at the control visit, all dogs had undetectable cTnT concentration (<0.01 ng/mL). A study in dogs with GDV described similar findings, with no significant changes in cTnT concentrations immediately after surgery but increased concentrations on the 2 days after presentation. 25, 26 A study evaluating cTnI concentrations in dogs with SIRS identified a higher prevalence of increased cTnI concentrations at presentation (35/60 dogs) and during hospitalization, but also did not find significant variations from day to day. 19 A study comparing cTnT and cTnI in dogs with SIRS admitted to an ICU found a higher prevalence of increased cTnI concentrations. This difference in detection rate can be explained by the lower sensitivity of cTnT compared to cTnI to detect myocardial lesions, or by the timing of sampling compared to the start of the disease process (as admission to the ICU likely takes place later than admission to an emergency department). 20 The use of a cTnI assay in the present study may have resulted in the detection of increased concentrations in a larger proportion of SIRS patients, but cTnT was chosen for financial reasons. 26, 28 NT-proBNP changed significantly over time, with concentrations at T24, T72, and T120 significantly higher than concentrations at T0, T6, T12, and the control visit. Most of the research performed in veterinary medicine on NT-proBNP has focused on cardiac disease. [53] [54] [55] A recent study evaluating BNP in dogs with noncardiac disease (eg, neurological and gastrointestinal disease) demonstrated a moderate increase of natriuretic peptides in these patients. 34 BNP and NT-proBNP concentrations cannot be directly compared. However, as SIRS has a high potential to induce cardiac effects in human medicine, the more markedly increased NT-proBNP concentrations in our study focused on dogs with SIRS compared to this previous study therefore do not seem surprising. 35 Finding higher concentrations at T24, T72, and T120 is in agreement with studies on SIRS and sepsis in human patients. The time point with the highest plasma NT-proBNP measurement varied across studies in people, from the day of admission to day 2 and day 5 after admission, 22, 56 which is probably due to the difficulty in determining the time of onset of the disease. Nevertheless, peak concentrations are likely to be found more than 2 days after hospitalization in people. 9, 15, 21 Detectable cTnT concentrations during hospitalization were associated with poor short-term prognosis. Cardiac troponin T and I are well-accepted prognostic biomarkers in human intensive care units. 10, 11, 23, 57 In veterinary medicine, increased concentrations of cTns have been observed in infectious disease patients, trauma patients, GDV patients, and patients suffering from systemic diseases 25, 26, [28] [29] [30] [58] [59] [60] [61] [62] and are correlated with poor prognosis in some of these reports. 25, 26, 28, 30 Reports that evaluate plasma concentrations of cTnI and cTnT in dogs with SIRS have confirmed their prognostic value, identifying differences in concentration between survivors and nonsurvivors. 19, 20, 33 In one report, additional sampling to measure cTnI concentrations on day 2 or 3 (or evaluation of concentration changes) did not add value to the prognostic information. 19 Although the incidence of increased cTnI concentrations has been reported to be higher than for cTnT, cTnI and cTnT carried similar prognostic information. 20, 33 cTnT concentrations have been established as interesting markers to predict prognosis of canine SIRS patients, but cutoff limits remain to be determined. 33 As cTnT (and cTnI) can remain increased up to 7 or 10 days after an insult, the kinetics of cTnT are difficult to evaluate, and they may be less useful for evaluation of disease progression. 63, 64 In the present study, NT-proBNP concentrations were not significantly correlated with prognosis. Previous studies in dogs tended to evaluate natriuretic peptides at presentation, while higher concentrations should be expected later during hospitalization. This delay in the rise of NT-proBNP limits its use as a prognostic marker in a clinical veterinary emergency care setting. At later timepoints, the group size in this study rapidly decreased, which may have impacted the likelihood to identify significant differences between survivors and nonsurvivors. A recently published meta-analysis in human patients with sepsis concluded that NT-proBNP concentrations are significantly associated with risk of mortality. 22 This meta-analysis also concluded that increased NT-proBNP concentrations in the presence of SIRS or sepsis do not indicate cardiac dysfunction, but normal NT-proBNP concentrations rule out the need for further cardiac investigation. 22 The lack of a significant difference in NT-proBNP concentration between survivors and nonsurvivors in this study should be confirmed in a larger cohort of patients with SIRS. The observed increased NT-proBNP concentrations in this study may be explained by myocardial hibernation, but also may have been increased due to increased cardiac wall stress after volume resuscitation, 65 the presence of lung injury, acute respiratory distress syndrome, or thromboembolism. 6 There are several limitations to the present study. Dogs that were considered too unstable by the attending clinician were removed from the study, and therefore, more severely ill patients were less likely to enter the study. Consequently, findings might have been different if all dogs were included, regardless of their clinical status. Because sampling times were standardized with relation to the timing of presentation to the emergency department, disease may have been present for variable amounts of time prior to enrollment, and this may have altered the kinetics of the studied biomarkers. In addition, a large proportion of our patients were euthanized at the owner's request, rather than based on specific study endpoints, which may have impacted our analysis of prognosis. In order to avoid any effect of financial considerations on the prognostic evaluation, all dogs that were euthanized for financial or unspecified reasons were removed from the prognosis analysis.
TA B L E 2 P-values for cTnT concentrations between different time points in all canine SIRS patients
In the present study, 44 patients survived to discharge (64%), which is similar to, 66 or better than 67 previous studies on clinical canine SIRS patients.
Samples with NT-proBNP concentrations above the upper limit of the assay (3,000 pmol/L) were not diluted to measure the exact concentration because of financial restrictions. Therefore, NT-proBNP concentration was underestimated in some samples. This did not prohibit the finding of significant changes, but may have underestimated the degree of those changes in NT-proBNP concentration. Similarly, a cTnT assay rather than a cTnI assay was used due to financial restrictions. The use of a cTnI assay may have resulted in a higher detection rate of increased troponin concentrations.
Our study demonstrates that cardiac biomarkers are often increased in dogs with SIRS presenting to the emergency department.
Additionally, this study confirms that the cTnT concentration was associated with survival in dogs with SIRS. Studies investigating the correlation of cardiac biomarkers with echocardiographic findings and inflammatory cytokines in canine patients with SIRS are warranted.
